Partial
Mostly Aligned
Patient Risk:
Medium
Summary
Overall partial alignment. The claims align with label-based interactions (ACE inhibitors, diuretics) and renal/cardiovascular risk concepts, but include multiple omissions and some statements not supported or contradicted by the label (notably ARB interactions, beta-blocker/CCB interactions, short-term use guidance, acetaminophen/aspirin guidance, and certain population-specific cautions).
Category Scores
Accurate Statements
Ibuprofen can reduce the effectiveness of ACE inhibitors (e.g., lisinopril).
DRUG INTERACTIONS - ACE-inhibitors
Ibuprofen can reduce the effectiveness of diuretics (e.g., hydrochlorothiazide).
DRUG INTERACTIONS - Diuretics
This can potentially raise blood pressure and increase risks of kidney damage or heart issues.
ADVERSE REACTIONS, DRUG INTERACTIONS - Renal Effects
Ibuprofen blocks prostaglandins that help these drugs dilate blood vessels and protect kidneys, countering their effects.
DRUG INTERACTIONS - ACE-inhibitors, DRUG INTERACTIONS - Diuretics
Diuretics: Ibuprofen causes fluid retention, making diuretics less effective at lowering blood pressure.
DRUG INTERACTIONS - Diuretics, ADVERSE REACTIONS - CARDIOVASCULAR
Ibuprofen inhibits kidney blood flow and prostaglandin production, which blood pressure meds rely on for optimal function.
DRUG INTERACTIONS - ACE-inhibitors, DRUG INTERACTIONS - Diuretics
Chronic use raises dangers like acute kidney injury.
ADVERSE REACTIONS, GERIATRIC USE, DRUG INTERACTIONS - Renal Effects
Blood pressure may spike.
ADVERSE REACTIONS
Kidney function can decline rapidly.
DRUG INTERACTIONS - Renal Effects, ADVERSE REACTIONS
Age over 65 makes it riskier.
GERIATRIC USE
Symptoms include swelling, fatigue, or elevated readings.
ADVERSE REACTIONS
They may adjust doses or monitor kidneys.
DRUG INTERACTIONS, ADVERSE REACTIONS
Unsupported Statements
Ibuprofen can reduce the effectiveness of ARBs (e.g., losartan).
Not supported by the provided label sections; ARB interaction not listed in DRUG INTERACTIONS sections provided.
Beta-blockers (e.g., metoprolol): Interactions are milder.
No explicit beta-blocker interaction detail in label excerpts provided.
Calcium channel blockers (e.g., amlodipine) have fewer issues.
No explicit CC blocker interaction detail in label excerpts provided.
Monitoring is advised with calcium channel blockers.
No explicit monitoring language for CC blockers in the provided label sections.
Short-term use (e.g., 1-2 days) poses lower risk for healthy adults.
Not supported by the provided label sections.
Use in those with kidney disease, heart failure, or hypertension raises these dangers.
While there are warnings, the exact phrasing is not present in the provided label sections.
This can lead to poor control, stroke risk, or heart strain.
Not explicitly stated in the provided label excerpts.
Stop use and seek medical help if noticed.
Not present in the provided label excerpts.
Acetaminophen (Tylenol) is first choice for pain and fever.
Not present in the label excerpts; this claim is not supported by the provided sections.
Acetaminophen has minimal blood pressure impact.
Not present in the label excerpts.
Naproxen has similar risks to ibuprofen.
Not present in the provided label sections.
Avoid naproxen too.
Not present in the provided label sections.
Occasional low-dose ibuprofen (200-400 mg) might be fine for young, healthy people with well-controlled BP.
Not present in the provided label sections.
Always check with a pharmacist or doctor first.
Not present in the provided label sections.
Diabetes makes it riskier.
Not present in the provided label sections.
Existing kidney issues make it riskier.
Not present in the provided label sections.
Contradictions
Low
AI Statement
Low-dose aspirin is okay for heart protection.
Label Reference
DRUG INTERACTIONS - Aspirin
Important Omissions
Explicit ARB interaction with NSAIDs (e.g., losartan) is not described in the Drug Interactions sections provided.
Importance:
Moderate
Clear, label-aligned guidance on acetaminophen as an alternative or preference for analgesia within hypertensive populations.
Importance:
Moderate
Explicit statements about naproxen risk relative to ibuprofen and potential avoidance as alternative NSAID are not provided.
Importance:
Moderate
Population-specific cautions beyond geriatric use (e.g., diabetes) are not described in the provided label sections.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
NSAID interactions with antihypertensive therapy pose potential cardiovascular and renal risks, especially with ACE inhibitors and diuretics; risk is amplified in older adults and those with renal impairment.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omissions of ARB interactions, CC-blocker monitoring guidance, and certain population-specific cautions; incorrect/unsupported statements (acetaminophen first line, aspirin safety) require correction.
Suggested Improvement
Add explicit ARB interaction language to Drug Interactions; clarify dosing/usage guidance (where label provides), include acetaminophen/aspirin guidance consistent with label; reinforce warnings for elderly and those with renal disease; remove unsupported assertions and ensure any monitoring guidance reflects label language.